Liposome Production Using Mixed Organic Solvents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing liposomes for pharmaceutical applications face challenges in achieving safety, stability, and uniform particle size, often relying on hazardous organic solvents and requiring additional processing steps, which complicates industrial-scale production and preservation stability.
Innovation Solution
A method involving the mixing of an oil phase with lipids dissolved in a mixed solvent of water-soluble and ester-based organic solvents, followed by stirring and evaporation, which allows for the production of liposomes without harmful solvents and additives, achieving an average particle size of 200 nm or less with uniform distribution and enhanced preservation stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chlorinated organic solvents such as dichloromethane and chloroform are used as water-immiscible organic solvents in the emulsification method, then liposome formation is achieved, but safety problems of working conditions and produced liposomes arise
Solution Approach 1:
The patent changes the chemical parameters of the organic solvent from chlorinated solvents (dichloromethane, chloroform) to non-chlorinated solvents (ether-based, ester-based, ketone-based). This parameter substitution maintains the solvent's functional properties (water immiscibility, lipid dissolution capability) while eliminating toxic harmful factors, thus resolving the contradiction between reliable liposome formation and safety
Solution Approach 2:
The patent employs readily available, inexpensive organic solvents (ether, ester, ketone) that can be easily removed by evaporation. These solvents serve their purpose during the emulsification process and are then completely eliminated, leaving no harmful residues in the final liposome product, thereby addressing both safety concerns and cost-effectiveness
2Manufacturing precision
If additional stabilizer or sizing process is added to achieve finer particle size and stable vesicles, then particle size control is improved, but device complexity and process steps increase
Solution Approach 1:
The patent extracts and eliminates the need for additional stabilizers and sizing processes by optimizing the core emulsification parameters. Through careful selection of organic solvent type and ratio, along with controlled stirring conditions, the method achieves fine particle size (200 nm or less) directly during the emulsification step itself, without requiring subsequent stabilization or sizing operations
Solution Approach 2:
The patent changes the emulsification parameters by using specific ratios of water-miscible to water-immiscible organic solvents (1:4 to 4:1 ratio) and controlling stirring speed (500-2000 rpm for 5-30 minutes). These parameter optimizations enable direct formation of uniformly sized liposomes (200 nm or less) during the emulsification process, eliminating the need for additional stabilizers or sizing steps
3Productivity
If chlorinated solvents are used in the emulsification method, then liposome production is achieved, but preservation stability and suppression of lipid decomposition after storage are compromised
Solution Approach 1:
The patent changes the chemical composition parameter of the organic solvent from chlorinated to non-chlorinated types (ether, ester, ketone). This substitution maintains the ability to dissolve lipids and form emulsions during production, while the absence of chlorinated compounds prevents catalytic effects that would accelerate lipid decomposition during storage, thereby improving preservation stability without sacrificing productivity
Solution Approach 2:
The patent uses volatile, easily removable organic solvents (ether, ester, ketone) that serve their function during the emulsification process and are then completely evaporated. Since these solvents are completely removed and do not remain in the final product, they cannot cause long-term degradation or lipid decomposition during storage, thus ensuring both production efficiency and long-term preservation stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the production of safe, stable, and uniformly sized liposomes suitable for pharmaceutical use, eliminating the need for hazardous solvents and additional sizing processes, while ensuring long-term preservation stability and suitability for industrial-scale production.
Implementation Method 1
a step of evaporating an organic solvent from the aqueous solution containing lipids
Data Source
Figure 1~2
AI summary
Provided is a method for producing a liposome having safety and stability. According to the present invention, it is possible to provide a method for producing a liposome, including a step of mixing an oil phase with at least one lipid dissolved in an organic solvent and a water phase and stirring an aqueous solution containing the lipids, and a step of evaporating the organic solvent from the aqueous solution containing the liposomes obtained in the stirring step, in which the organic solvent is a mixed solvent of a water-soluble organic solvent and an ester-based organic solvent.